Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia - PubMed (original) (raw)
. 1994 Nov 1;84(9):3105-12.
Affiliations
- PMID: 7949183
Free article
Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia
M B Diccianni et al. Blood. 1994.
Free article
Abstract
In T-cell acute lymphoblastic leukemia (T-ALL), p53 gene mutations were found in 12 of 51 patients in first relapse (24%). In a retrospective study, bone marrow samples at diagnosis were obtained from 9 of the 12 relapsed patients with p53 mutation; only one patient was found to harbor a p53 mutation at diagnosis. No further p53 mutations were identified in 18 unpaired diagnosis T-ALL samples. This is the first report of a p53 mutation in T-ALL at diagnosis. p53 mutations in relapsed T-ALL were clinically relevant. Patients with p53 mutations experience a shorter duration of survival than those patients without p53 mutations. Additionally, patients with p53 mutations were significantly less likely to have achieved a complete second remission from reinduction therapy than those patients without p53 mutations and experience a shorter duration of survival from relapse even when a second reinduction is obtained. Though primarily identified only at relapse, p53 mutations were also associated with a decreased duration of first remission and overall decrease in survival from diagnosis. Patients with p53 mutations had a 3.8-fold increase in risk of death than those patients without p53 mutations. These findings suggest that p53 mutation is associated with poor clinical outcome that is characterized by (1) a shortened duration of survival after first relapse; (2) a reduced response to reinduction therapy; (3) a shortened duration of first remission; and, hence, (4) an overall decreased duration of survival and increased risk of death.
Similar articles
- Mutations of the p53 and ras genes in childhood t(1;19)-acute lymphoblastic leukemia.
Kawamura M, Kikuchi A, Kobayashi S, Hanada R, Yamamoto K, Horibe K, Shikano T, Ueda K, Hayashi K, Sekiya T, et al. Kawamura M, et al. Blood. 1995 May 1;85(9):2546-52. Blood. 1995. PMID: 7727782 - Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase.
Hsiao MH, Yu AL, Yeargin J, Ku D, Haas M. Hsiao MH, et al. Blood. 1994 May 15;83(10):2922-30. Blood. 1994. PMID: 8180387 - Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia.
Kawamura M, Ohnishi H, Guo SX, Sheng XM, Minegishi M, Hanada R, Horibe K, Hongo T, Kaneko Y, Bessho F, Yanagisawa M, Sekiya T, Hayashi Y. Kawamura M, et al. Leuk Res. 1999 Feb;23(2):115-26. doi: 10.1016/s0145-2126(98)00146-5. Leuk Res. 1999. PMID: 10071127 - Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases.
Preudhomme C, Dervite I, Wattel E, Vanrumbeke M, Flactif M, Lai JL, Hecquet B, Coppin MC, Nelken B, Gosselin B, et al. Preudhomme C, et al. J Clin Oncol. 1995 Apr;13(4):812-20. doi: 10.1200/JCO.1995.13.4.812. J Clin Oncol. 1995. PMID: 7707106 - Exon 5 mutations in the p53 gene in relapsed childhood acute lymphoblastic leukemia.
Blau O, Avigad S, Stark B, Kodman Y, Luria D, Cohen IJ, Zaizov R. Blau O, et al. Leuk Res. 1997 Aug;21(8):721-9. doi: 10.1016/s0145-2126(97)80032-x. Leuk Res. 1997. PMID: 9379679
Cited by
- Targeting NOTCH1 in combination with antimetabolite drugs prolongs life span in relapsed pediatric and adult T-acute lymphoblastic leukemia xenografts.
Minuzzo S, Agnusdei V, Pinazza M, Amaro AA, Sacchetto V, Pfeffer U, Bertorelle R, Spinelli O, Serafin V, Indraccolo S. Minuzzo S, et al. Exp Hematol Oncol. 2023 Sep 4;12(1):76. doi: 10.1186/s40164-023-00439-6. Exp Hematol Oncol. 2023. PMID: 37667380 Free PMC article. - Prognostic Significance of Comprehensive Gene Mutations and Clinical Characteristics in Adult T-Cell Acute Lymphoblastic Leukemia Based on Next-Generation Sequencing.
Yin H, Hong M, Deng J, Yao L, Qian C, Teng Y, Li T, Wu Q. Yin H, et al. Front Oncol. 2022 Feb 24;12:811151. doi: 10.3389/fonc.2022.811151. eCollection 2022. Front Oncol. 2022. PMID: 35280829 Free PMC article. - Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations.
Wong J, Wall M, Corboy GP, Taubenheim N, Gregory GP, Opat S, Shortt J. Wong J, et al. Cold Spring Harb Mol Case Stud. 2020 Aug 25;6(4):a004994. doi: 10.1101/mcs.a004994. Print 2020 Aug. Cold Spring Harb Mol Case Stud. 2020. PMID: 32843425 Free PMC article. - Integrated Genomic Analysis of Chromosomal Alterations and Mutations in B-Cell Acute Lymphoblastic Leukemia Reveals Distinct Genetic Profiles at Relapse.
Forero-Castro M, Montaño A, Robledo C, García de Coca A, Fuster JL, de Las Heras N, Queizán JA, Hernández-Sánchez M, Corchete-Sánchez LA, Martín-Izquierdo M, Ribera J, Ribera JM, Benito R, Hernández-Rivas JM. Forero-Castro M, et al. Diagnostics (Basel). 2020 Jul 4;10(7):455. doi: 10.3390/diagnostics10070455. Diagnostics (Basel). 2020. PMID: 32635531 Free PMC article. - TP53 alterations in relapsed childhood acute lymphoblastic leukemia.
Yu CH, Chang WT, Jou ST, Lin TK, Chang YH, Lin CY, Lin KH, Lu MY, Chen SH, Wu KH, Wang SC, Chang HH, Su YN, Hung CC, Lin DT, Chen HY, Yang YL. Yu CH, et al. Cancer Sci. 2020 Jan;111(1):229-238. doi: 10.1111/cas.14238. Epub 2019 Dec 5. Cancer Sci. 2020. PMID: 31729120 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous